Zacks Investment Research upgraded shares of APPRICUS BIOSCI (APRI) from NEUTRAL to OUTPERFORM on December 31, 2014, with a target price of $1.10.
Apricus Bio operates in the pharmaceutical industry and focuses on research and development in the area of drug delivery. Its proprietary drug delivery technology is called NexACT . Backed by revenue generating CRO business, Bio-Quant, Inc. and its NexMed USA subsidiary, Apricus Bio has leveraged the flexibility of its proven NexACT drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. The Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. Apricus Bio was formerly known as NexMed, Inc and is headquartered in San Diago, California.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on APPRICUS BIOSCI (APRI),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment